Strattera + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fetal Alcohol Syndrome
Conditions
Fetal Alcohol Syndrome, Attention Deficit Disorder With Hyperactivity (ADHD), Attention Deficit Disorder (ADD)
Trial Timeline
Aug 1, 2005 → Apr 22, 2015
NCT ID
NCT00417794About Strattera + Placebo
Strattera + Placebo is a phase 1 stage product being developed by Eli Lilly for Fetal Alcohol Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00417794. Target conditions include Fetal Alcohol Syndrome, Attention Deficit Disorder With Hyperactivity (ADHD), Attention Deficit Disorder (ADD).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00417794 | Phase 1 | Completed |
Competing Products
3 competing products in Fetal Alcohol Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Anti-(integrin beta-3) human monoclonal antibody | Rallybio | Phase 2 | 44 |
| Genotonorm (Somatropin) | Pfizer | Phase 3 | 76 |
| somatropin + somatropin | Sanofi | Phase 3 | 76 |